Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 83Lung Neoplasms 29Neoplasms 7Neoplasm Metastasis 7Carcinoma 5Colorectal Neoplasms 4NSCLC 3Breast Neoplasms 3Brain Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Non Small Cell Lung Cancer Metastatic 2Multiple Myeloma 2Meningeal Carcinomatosis 2Lymphoma 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stage II-IIIB Non-small Cell Lung Carcinoma 1Stage IB-IIIA Non-small Cell Lung Carcinoma 1Solid Tumor, Adult 1Solid Tumor 1Small Cell Lung Carcinoma 1

Interventions

pembrolizumab 97Carboplatin 68Paclitaxel 57Cyclophosphamide 41Capecitabine 31Specimen Handling 28sacituzumab govitecan 26130-nm albumin-bound paclitaxel 25Gemcitabine 22olaparib 21Magnetic Resonance Spectroscopy 21Doxorubicin 21Taxes 20Albumin-Bound Paclitaxel 20Biopsy 19Drug Therapy 16Nivolumab 15atezolizumab 14toripalimab 12Radiotherapy 12Epirubicin 12durvalumab 11eribulin 10Docetaxel 10Cisplatin 10Bevacizumab 10fludarabine 8Standard of Care 7Radiation 7Injections 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × osimertinib × 1 year × Clear all
NCT06618287 2026-05-07

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Recruiting
416 enrolled
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡